California Signals Support for Longevity and Healthspan With Senate Resolution

Although nonbinding, SR 104 reflects growing institutional recognition of longevity and healthspan as emerging public policy priorities in the nation’s largest state and a leading hub for health and life sciences innovation.

The Science and Economics Behind the Resolution

SR 104 is grounded in a stark set of findings. The resolution identifies aging as the “primary driver of chronic diseases that impair and kill millions of Americans each year.” It notes that the risk of developing chronic disease rises exponentially with age, making chronological age the leading risk factor for the top nine causes of nonaccidental death in the United States, including heart disease, cancer, stroke, Alzheimer’s, diabetes, and kidney disorders. 

The economic rationale is equally significant. SR 104 cites hundreds of billions of dollars in annual costs associated with cardiovascular disease, cancer, and diabetes, and points out that chronic conditions collectively drive trillions in health care spending each year. Critically, the resolution observes that while average lifespan increased by more than 30 years over the past century, healthspan — the years lived free of disease — has risen only modestly, leaving the average American living approximately 15 years with one or more serious illnesses. 

What the Resolution Does

SR 104 establishes a policy framework encouraging greater integration of longevity and healthy aging principles into California’s public health and innovation ecosystem. Specifically, the resolution:

• Supports targeting the biological processes of aging as a strategy to prevent or delay chronic disease onset.

• Encourages investment in research grants, public-private partnerships, and regulatory frameworks that support the development of therapies to slow, prevent, or reverse aspects of biological aging.

• Calls on the California Department of Public Health and Department of Aging to incorporate the science of aging into chronic disease prevention and healthy aging strategies, including education, outreach, and demonstration programs.

• Encourages partnerships among California’s academic research institutions, health plans, and biotechnology firms to pilot innovative aging interventions that improve healthspan and reduce long-term care costs.

Why It Matters

A Senate resolution does not create legal obligations or change regulatory standards. But SR 104 may help shape future conversations around research priorities, demonstration initiatives, public funding, and prevention-oriented models of care.

For stakeholders across the longevity ecosystem, the resolution serves as another signal that healthy aging is increasingly moving toward mainstream policy discussion. Biotech innovators, health systems, health plans, and consumer health companies may find growing opportunities to participate in efforts aimed at extending healthy years of life and reducing chronic disease burden.

At the same time, important questions remain regarding evidence generation, validation of aging-related biomarkers, reimbursement pathways, and how regulators will distinguish wellness products, clinical interventions, and regulated medical technologies. As the longevity space matures, policy development at both the state and federal levels will play an increasingly important role in determining how innovation reaches patients and consumers.